Delving into the Latest Updates on Carmustine with Synapse

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

BCNU, BIODEL carmustine, bis-chloroethylnitrosourea

+ [19]

Target

DNA

Action

inhibitors

Mechanism

DNA inhibitors(DNA inhibitors), DNA alkylating agents

Therapeutic Areas

NeoplasmsImmune System DiseasesNervous System Diseases+ [2]

Active Indication

Brain metastasesBrain Stem GliomaEpendymoma+ [9]

Inactive Indication

Glioblastoma MultiformeGliosarcomaOligodendroglioma+ [3]

Originator Organization

Emcure Pharmaceuticals Ltd.

Active Organization

medac Gesellschaft für klinische Spezialpräparate mbH

Tianjin Jinyao Pharmaceutical Co., Ltd.Avet Lifesciences Ltd.

+ [4]

Inactive Organization

Accord Healthcare, Inc.Direct Therapeutics, Inc.

Eisai, Inc.

+ [1]

License Organization-

Drug Highest PhaseApproved

First Approval Date

United States (07 Mar 1977),

Brain CancerHodgkin's LymphomaMultiple Myeloma+ [1]

RegulationOrphan Drug (United States), Orphan Drug (European Union), Orphan Drug (Japan)

Login to view timeline

Structure/Sequence

Molecular FormulaC5H9Cl2N3O2

InChIKeyDLGOEMSEDOSKAD-UHFFFAOYSA-N

CAS Registry154-93-8

This multicenter, open-label, trial aims to evaluate the efficacy and safety of orelabrutinib in combination with rituximab with optional autologous hematopoietic stem cell transplantation in patients with non-high-risk mantle cell lymphoma (MCL). The primary objective is to assess the optimal complete response (CR) rate during the induction phase, with secondary objectives including progression-free survival (PFS), overall survival (OS), objective response rate (ORR), and safety. Exploratory analysis will investigate the correlation between tumor biomarkers and treatment efficacy.

Start Date01 Jul 2025

Sponsor / Collaborator

Ruijin Hospital

[+6]

NCT06687772

/ RecruitingPhase 2IIT

Safety and Feasibility Study for CNS-Relapse Prevention in High-Risk Diffuse Large B-cell Lymphoma With Thiotepa-based Autologous Stem Cell Transplant (CNS-PHLAT)

A serious consequence of systemic diffuse large B-cell lymphoma (DLBCL) is secondary central nervous system (CNS) relapse, which occurs in approximately 5% of all patients. Many CNS relapses occur within the first year after completion of frontline treatment and are associated with significantly increased mortality; thus, it is important to tailor frontline treatment to provide prophylaxis against CNS relapse in those patients who are determined to be high-risk.
Autologous stem cell transplantation (ASCT) is standard of care for patients with DLBCL who relapse one year or more after first remission, and it has been shown to improve progression-free survival for patients with primary CNS lymphoma.
The four-drug BEAM regimen (carmustine, etoposide, cytarabine, and melphalan) is the preferred conditioning regimen for DLBCL patients undergoing ASCT; however, patients with primary CNS lymphoma receive thiotepa plus carmustine as their conditioning regimen due to its better CNS penetration.
This study tests the hypothesis that consolidation thiotepa/carmustine ASCT in first complete remission will reduce the risk of CNS relapse in transplant-eligible patients with DLBCL with no prior CNS disease at high risk of secondary CNS recurrence.

Start Date16 Jan 2025

Sponsor / Collaborator

Washington University School of Medicine

NCT06692452

/ RecruitingPhase 2IIT

A Phase II Study of Tazemetostat in Combination With CHOP for Previously Untreated T Cell Lymphoma

This research is being done to evaluate tazemetostat in combination with CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone) chemotherapy as a possible treatment for peripheral T-Cell Lymphoma (PTCL).
The name of the study drugs involved in this study are:
* Tazemetostat (a type of inhibitor for Enhancer of Zeste Homolog 2 (EZH2))
* Standard of care CHOP therapy:
* Cyclophosphamide (a type of alkylating agent)
* Doxorubicin (a type of anthracycline antibiotic)
* Vincristine (a type of vinca alkaloid)
* Prednisone (a type of corticosteroid)
* Standard of care BEAM conditioning regimen for autologous stem cell transplant:
* Carmustine (a type of alkylating agent)
* Etoposide (a type of Topoisomerase II inhibitor)
* Cytarabine (a type of antineoplastic)
* Melphalan (a type of alkylating agent)

Start Date24 Dec 2024

Sponsor / Collaborator

Dana-Farber Cancer Institute, Inc.

[+1]

100 Clinical Results associated with Carmustine

Login to view more data

100 Translational Medicine associated with Carmustine

Login to view more data

100 Patents (Medical) associated with Carmustine

Login to view more data

5,200

Literatures (Medical) associated with Carmustine

01 Nov 2025·INTERNATIONAL JOURNAL OF PHARMACEUTICS

Evaluation of drug distributions in brain tumor therapy: An in silico comparative study of multi-side-hole and standard end-hole catheters in convection-enhanced delivery

Article

Author: Si, Xinhui ; Wang, Ying ; Cao, Limei ; Wang, Wei ; Lou, Ziyi ; Zhu, Jing ; Zhang, Aili ; Zhang, Xuelan

Convection-enhanced delivery (CED) is a promising technique for treating brain tumors by enabling drugs to bypass the blood-brain barrier (BBB). The types of catheters and physicochemical properties of drugs both influence drug distribution within tumors. In this study, based on a 3D brain model reconstructed from magnetic resonance (MR) images, a Computational Fluid Dynamics (CFD) simulation is employed to investigate the effects of a multi-side-hole catheter (MSHC) on the CED administration of six anticancer drugs. Results indicate that reducing catheter diameter at the same infusion rate increases the effective volumes of all six drugs. When administered through the MSHC, five of the six drugs (excluding paclitaxel) show increased effective distribution volumes, while none of the drugs demonstrate higher volume-averaged concentrations. In summary, compared to the standard end-hole catheter (SEHC), the MSHC shows superior therapeutic efficacy for doxorubicin, cisplatin, fluorouracil, and carmustine. When methotrexate is administered via MSHC, it is necessary to balance the increased distribution volume against the reduced volume-averaged concentration. Paclitaxel is more suitable for administration in the SEHC, especially with a low infusion rate and a small-diameter catheter. These findings can provide recommendations for the clinical implementation of CED.

01 Oct 2025·EXPERIMENTAL NEUROLOGY

HDAC6 inhibition enhances peroxiredoxin 1 acetylation to mitigate oxidative stress and seizure activity in focal cortical dysplasia

Article

Author: Kumar, Sonali ; Sharma, M C ; Lalwani, Sanjeev ; Banerjee, Jyotirmoy ; Siraj, Fouzia ; Tripathi, Manjari ; Shanker, Ozasvi R ; Parambath, Sreestha Dinesh ; Dixit, Aparna Banerjee ; Chandra, P Sarat

BACKGROUND:

Focal cortical dysplasia (FCD) is one of the most common causes of drug-resistant epilepsy (DRE) which is characterized by malformations of the cortex and molecular dysregulation. Despite advancements in classification and surgical interventions the pathophysiology behind it remains unclear and non-surgical treatment options remain limited. Oxidative stress, induced by imbalances of reactive oxygen species (ROS) and antioxidant defences, has been involved in the pathophysiology of FCD. This study evaluates the role of histone deacetylase 6 (HDAC6) in modulating oxidative stress and seizure activity through the acetylation status of peroxiredoxin-1 (Prdx1), a key antioxidant enzyme.

METHODS:

Cortical samples from FCD Type II patients and BCNU rat model were analysed using qRT-PCR, immunoblotting, and co-immunoprecipitation to assess the expression of HDAC6, and acetylation status of Prdx1. ROS levels were measured using dichlorofluorescin diacetate (DCFDA) assay. Pharmacological inhibition of HDAC6 using Tubastatin A (TubA) was evaluated for its effects on oxidative stress, Prdx1 acetylation, and seizure activity induced by pilocarpine.

RESULTS:

HDAC6 was found to be significantly upregulated in the cortical samples from FCD Type II tissues and BCNU rats. Increased HDAC6 activity reduced Prdx1 acetylation, leading to elevated ROS levels and oxidative stress. TubA treatment restored Prdx1 acetylation, reduced oxidative stress, and significantly decreased seizure frequency and increased seizure latency in the BCNU model.

CONCLUSION:

This study identifies HDAC6 as a key regulator of oxidative stress and epileptogenesis in FCD through Prdx1 deacetylation. Pharmacological inhibition of HDAC6 offers a promising therapeutic strategy for managing FCD-associated epilepsy by restoring antioxidant defences and mitigating seizure activity. Further studies are warranted to explore its clinical potential.

01 Oct 2025·CLINICAL NEUROLOGY AND NEUROSURGERY

Overall survival after carmustine wafers implantation for newly-diagnosed high grade glioma. A nationwide population-based controlled propensity score-matched analysis

Article

Author: Metellus, Philippe ; Tuppin, Philippe ; Weller, Joconde ; Jecko, Vincent ; Depond, Charles Champeaux

OBJECTIVE:

Widespread use of carmustine wafers (CW) for high-grade gliomas (HGG) has been limited by uncertainties about its efficacy. This study aimed to evaluate the overall survival (OS) of patients who underwent CW implantation after newly-diagnosed HGG resection.

METHODS:

In this retrospective study, we processed the French medico-administrative national database to retrieve ad hoc cases. Propensity score-matched (PSM) analysis was performed to reduce bias from confounding patient-related variables and, OS was compared between the two groups.

RESULTS:

A total of 2956 newly-diagnosed HGG patients who were post-operatively treated according the chemoradiotherapeutic Stupp regimen between the 1st January 2008 and the 31st December 2019 were extracted from the SNDS. 1518 (51.4 %) of these patients had CW implantation at HGG surgery. From the total recruited, 1604 (54.3 %) had missing data for at least 1 of the variables used to calculate the PS and, thus had to be excluded. Of the 1352 remaining subjects, we paired 500 treated patients with 852 controls. The median survival time for the treated group was 1.53 versus 1.42 years for the control group (p = 0.299). The estimated difference in restricted mean survival time between groups at 1, 2, 3 and 5 years were 0.02, _95 %CI[-0.02-0.05], p = 0.326; 0.06, _95 %CI[-0.04-0.16], p = 0.213; 0.11, _95 %CI[-0.04-0.27], p = 0.153 and 0.13, _95 %CI[-0.12-0.37], p = 0.322 respectively.

CONCLUSION:

CW implantation with standard chemoradiotherapeutic treatment after newly-diagnosed HGG surgery did not increase the OS of patients.

26

News (Medical) associated with Carmustine

18 Oct 2025

·www.globenewswire.com

General Oncology Announces Promising Preliminary Phase 1 Results from SHARON Trial Presented at ESMO 2025

Novel regimen GO-4, combining melphalan, BCNU, hydroxocobalamin, ascorbic acid, and autologous stem cells shows manageable adverse reactions and a strong signal of efficacy in patients with BRCA-related pancreatic cancerBOSTON, Oct. 18, 2025 (GLOBE NEWSWIRE) -- General Oncology, Inc. (“General Oncology” or the “Company”), a clinical-stage biopharmaceutical company dedicated to pioneering first-in-class medicines for metastatic cancers, today announced preliminary results from its ongoing Phase 1 SHARON trial (NCT04150042), evaluating GO-4: the Company’s patented Advanced Redox Modulation regimen consisting of melphalan, BCNU, hydroxocobalamin, ascorbic acid, and autologous stem cell infusion in patients with advanced pancreatic ductal adenocarcinoma (PDAC) or breast cancer harboring an inherited BRCA/PALB2 mutation. The data will be featured in a poster presentation at the European Society for Medical Oncology (ESMO) Congress 2025. “GO-4 is a therapy designed to achieve major log reductions in tumor cell burden. BRCA-mutated cancer cells are hypersensitive to DNA cross-linking agents, but reversion mutations can lead to drug resistance. GO-4 uses Advanced Redox Modulation to impair DNA repair and sensitize resistant cells to melphalan,” said Arnold Glazier, M.D., Chief Scientific Officer of General Oncology. “We are encouraged by the data demonstrating that GO-4 has a manageable safety profile and a strong signal of efficacy, with two stage IV pancreatic cancer patients remaining progression-free, for 4 years and 2 years after two cycles of GO-4 without additional treatment. We are committed to further exploring the full therapeutic potential of this combination therapy with continued research.” Presentation details and key highlights from the preliminary analysis are summarized below: Title: The SHARON Trial: Melphalan, BCNU, Hydroxocobalamin, Ascorbic Acid, and Stem Cells for Pancreatic and Breast Cancer and an Inherited BRCA/PALB2 MutationAbstract Number: 2228PPresenter: Kenneth H. Yu, M.D., Memorial Sloan Kettering Cancer Center, Principal InvestigatorDate and Time: Sunday, October 19 at 12:00–12:45 CESTLocation: Poster Area, Hall 25Key highlights: Eleven patients with metastatic PDAC and one patient with breast cancer received one to two rounds of treatment, six weeks apart; seven patients had progressive disease at enrollment.Safety was the primary endpoint, and no treatment-related mortality or long-term toxicities were reported.In patients with PDAC who had stable or responding disease at enrollment (N = 5), median progression-free survival was 14.2 months, with N = 2 free of disease at 48 and 23 months with no therapy subsequent to two cycles of GO-4. Kenneth H. Yu, M.D., Memorial Sloan Kettering Cancer Center, principal investigator of the SHARON trial, added, “We are always looking to expand treatment options, particularly for patients with advanced diseases who may have limited treatment options. The preliminary data from the SHARON trial demonstrating feasibility and a strong signal of efficacy in patients with BRCA-mutated pancreatic cancer are highly encouraging. The durable responses highlight the need for further clinical evaluation of this approach.” The SHARON trial is ongoing and will be expanding to include patients without a BRCA or PALB2 mutation, and General Oncology plans to continue evaluating outcomes and long-term follow-up in this high-need patient population. About the SHARON TrialThe SHARON trial is a Phase 1 study designed to evaluate the safety, feasibility, and preliminary efficacy of GO-4, the Company’s patented Advanced Redox Modulation regimen consisting of melphalan, BCNU, hydroxocobalamin, ascorbic acid, and autologous stem cell infusion in patients with advanced pancreatic or breast cancer. Patients enrolled to date have had an inherited BRCA/PALB2 mutation. For the remainder of the trial, patients with or without an inherited BRCA/PALB2 mutation will be able to enroll. About General Oncology, Inc.General Oncology is a clinical-stage biopharmaceutical company dedicated to pioneering first-in-class medicines for metastatic cancers and other proliferative diseases. The Company is developing GO-4, an investigational therapy for metastatic cancers, currently completing the Phase 1 SHARON trial (NCT04150042) for metastatic cancers in the setting of a BRCA1/2 or PALB2 mutation. With a commitment to innovation, General Oncology is focused on advancing transformative therapies for cancer patients. For more information about General Oncology, please visit www.generaloncology.com. Forward-Looking StatementsThis press release contains forward-looking statements within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995 and applicable securities laws. Forward-looking statements can be identified by words such as “designed to,” “will,” and similar references to future periods. Examples of forward-looking statements include, among others, statements we make regarding the expectations, plans, and prospects generally, and specifically for the SHARON trial, and General Oncology’s drug development programs. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based only on our management’s current beliefs, expectations and assumptions regarding the future of our business, future plans and strategies, projections, anticipated events and trends, the economy and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of our control. Our actual results and financial condition may differ materially from those indicated in the forward-looking statements. Therefore, you should not rely on any of these forward-looking statements. Important factors that could cause our actual results and financial condition to differ materially from those indicated in the forward-looking statements include, among others, the development and regulatory approval of investigational therapies, patient enrollment, trial execution, safety and efficacy outcomes, and other risks that may be detailed in General Oncology’s filings with the Securities and Exchange Commission. Any forward-looking statements made by us in this press release is based only on information currently available to us and speaks only as of the date on which it is made. General Oncology undertakes no obligation to update or revise any forward-looking statements, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise. Investor Contact:Abid Ansari(617) 468-4646ir@generaloncology.com Media Contact:Madelin Hawtinmhawtins@lifescicomms.com

Clinical ResultPhase 1ASCO

15 Oct 2025

·www.globenewswire.com

General Oncology to Present Preliminary Phase 1 Results from SHARON Trial in Patients with BRCA/PALB2-mutated Pancreatic and Breast Cancer at ESMO 2025

BOSTON, Oct. 13, 2025 -- General Oncology, Inc. (“General Oncology” or the “Company”), a clinical-stage biopharmaceutical company dedicated to pioneering first-in-class medicines for metastatic cancers, today announced that it will deliver a poster presentation featuring preliminary results from its ongoing Phase 1 SHARON trial (NCT04150042) evaluating GO-4: the Company’s patented Advanced Redox Modulation regimen consisting of melphalan, BCNU, hydroxocobalamin, ascorbic acid, and autologous stem cell infusion in patients with advanced pancreatic ductal adenocarcinoma or breast cancer harboring an inherited BRCA/PALB2 mutation at the upcoming European Society of Medical Oncology (ESMO) Congress 2025, taking place October 17-21 in Berlin, Germany. Title: The SHARON Trial: Melphalan, BCNU, Hydroxocobalamin, Ascorbic Acid, and Stem Cells for Pancreatic and Breast Cancer and an Inherited BRCA/PALB2 Mutation Abstract Number: 2228P Presenter: Kenneth H. Yu, M.D., Memorial Sloan Kettering Cancer Center, Principal Investigator Date and Time: Sunday, October 19 at 12:00–12:45 CEST Location: Poster Area, Hall 25 The SHARON trial is a Phase 1 study designed to evaluate the safety, feasibility, and preliminary efficacy of GO-4, the Company’s patented Advanced Redox Modulation regimen consisting of melphalan, BCNU, hydroxocobalamin, ascorbic acid, and autologous stem cell infusion in patients with advanced pancreatic or breast cancer. Patients enrolled to date have had an inherited BRCA/PALB2 mutation. For the remainder of the trial, patients with or without an inherited BRCA/PALB2 mutation will be able to enroll. General Oncology is a clinical-stage biopharmaceutical company dedicated to pioneering first-in-class medicines for metastatic cancers and other proliferative diseases. The Company is developing GO-4, an investigational therapy for metastatic cancers, currently completing the Phase 1 SHARON trial (NCT04150042) for metastatic cancers in the setting of a BRCA1/2 or PALB2 mutation. With a commitment to innovation, General Oncology is focused on advancing transformative therapies for cancer patients. The content above comes from the network. if any infringement, please contact us to modify.

ASCOClinical Result

17 Apr 2025

·www.globenewswire.com

VIVUS Announces Enrollment of First Patient in Phase 2 Clinical Trial Assessing Ethanol-Free Carmustine as a Component of High-Dose Chemotherapy Prior to Transplant in Patients with Hodgkin or Non-Hodgkin Lymphoma

— Innovative ethanol-free formulation intended to provide improved safety and advance care for patients undergoing high-dose conditioning therapy prior to autologous hematopoietic cell transplantation (AHCT) — First patient dosed at City of Hope National Medical Center April 14, 2025 -- VIVUS LLC, a biopharmaceutical company committed to the development and commercialization of innovative therapies that focus on advancing treatments for patients with serious unmet medical needs, today announced the first patient has been enrolled in a Phase 2 clinical trial evaluating VI-0609, an innovative ethanol-free formulation of carmustine, as a component of high-dose conditioning chemotherapy in patients with refractory or relapsed Hodgkin or non-Hodgkin lymphoma undergoing autologous hematopoietic cell transplant (AHCT). While the most commonly used conditioning regimen (BEAM) includes carmustine formulated with ethanol, VI-0609 is expected to improve safety of this important chemotherapy agent. “The initiation of this trial further demonstrates VIVUS’ commitment and ability to advance innovative drug formulations that can improve patient outcomes,” said John Amos, Chief Executive Officer at VIVUS LLC. “Conditioning regimens prior to AHCT are arduous, and VI-0609 may help to reduce patient burden by improving the safety profile and enabling shorter infusion times compared with high-dose BiCNU. Consequently, we believe that VI-0609 will provide benefit to treatment centers, health systems and patients.” The Phase 2 study (NCT06915246) is a randomized multicenter trial designed to evaluate the effects of VI-0609 versus BiCNU in the BEAM high-intensity conditioning regimen for AHCT in subjects with lymphomas. The primary objectives are to evaluate infusion-related toxicities for VI-0609/BiCNU within 24 hours post infusion and unacceptable toxicities for VI-0609/BiCNU from start of BEAM through Day 30 post-AHCT. “While BEAM is an effective conditioning regimen for AHCT, it is associated with toxicities harmful to patients, such as facial pain, vomiting and swelling of the tongue, some of which likely result from the high levels of ethanol that patients receive during BiCNU infusion,” said Geoffrey Shouse, D.O., Ph.D., Principal Investigator and Assistant Professor, Division of Lymphoma, Department of Hematology & Hematopoietic Cell Transplantation, City of Hope. “As an ethanol-free carmustine formulation, VI-0609 holds promise as an alternative component of BEAM that can effectively prepare patients for AHCT with fewer toxicities. City of Hope is a world leader in setting high standards for stem cell transplantation and improving patient outcomes and this would be an important advancement in the treatment of relapsed and refractory lymphomas.” “We’re incredibly excited to embark on the launch of our carmustine pipeline. This program, fueled by our strong development engine, represents a significant leap forward in our commitment to patients,” said Santosh T. Varghese, MD, President VIVUS Global Pharmaceutical Development and Chief Medical Officer at VIVUS LLC. “At VIVUS, we believe that by leveraging our robust scientific expertise and pushing the boundaries of innovation, we aim to deliver hope and improved outcomes to patients facing refractory or relapsed Hodgkin or non-Hodgkin lymphoma.” City of Hope National Medical Center is one of the largest and most advanced cancer research and treatment organizations in the United States, with its National Medical Center in Los Angeles ranked among the nation’s top 5 cancer centers by U.S. News & World Report. VIVUS is a biopharmaceutical company committed to the development and commercialization of innovative therapies that focus on advancing treatments for patients with serious unmet medical needs. For more information about the Company, please visit http://www.vivus.com. VIVUS has developed VI-0609, an innovative ethanol-free formulation of carmustine for injection. This formulation is expected to decrease infusion related reactions versus the current BiCNU ethanol based formulation utilized in high-dose carmustine treatment for myeloablative conditioning. The content above comes from the network. if any infringement, please contact us to modify.

Cell Therapy

100 Deals associated with Carmustine

Login to view more data

External Link

KEGG	Wiki	ATC	Drug Bank
D00254	Carmustine	L01AD01	DB00262

R&D Status

Approved

10 top approved records.

Login

to view more data

Indication	Country/Location	Organization	Date
Brain metastases	European Union	medac Gesellschaft für klinische Spezialpräparate mbH	18 Jul 2018
Brain metastases	Iceland	medac Gesellschaft für klinische Spezialpräparate mbH	18 Jul 2018
Brain metastases	Liechtenstein	medac Gesellschaft für klinische Spezialpräparate mbH	18 Jul 2018
Brain metastases	Norway	medac Gesellschaft für klinische Spezialpräparate mbH	18 Jul 2018
Brain Stem Glioma	European Union	medac Gesellschaft für klinische Spezialpräparate mbH	18 Jul 2018
Brain Stem Glioma	Iceland	medac Gesellschaft für klinische Spezialpräparate mbH	18 Jul 2018
Brain Stem Glioma	Liechtenstein	medac Gesellschaft für klinische Spezialpräparate mbH	18 Jul 2018
Brain Stem Glioma	Norway	medac Gesellschaft für klinische Spezialpräparate mbH	18 Jul 2018
Ependymoma	European Union	medac Gesellschaft für klinische Spezialpräparate mbH	18 Jul 2018
Ependymoma	Iceland	medac Gesellschaft für klinische Spezialpräparate mbH	18 Jul 2018
Ependymoma	Liechtenstein	medac Gesellschaft für klinische Spezialpräparate mbH	18 Jul 2018
Ependymoma	Norway	medac Gesellschaft für klinische Spezialpräparate mbH	18 Jul 2018
Medulloblastoma	European Union	medac Gesellschaft für klinische Spezialpräparate mbH	18 Jul 2018
Medulloblastoma	Iceland	medac Gesellschaft für klinische Spezialpräparate mbH	18 Jul 2018
Medulloblastoma	Liechtenstein	medac Gesellschaft für klinische Spezialpräparate mbH	18 Jul 2018
Medulloblastoma	Norway	medac Gesellschaft für klinische Spezialpräparate mbH	18 Jul 2018
Glioblastoma	United States	Azurity Pharmaceuticals, Inc.	23 Sep 1996
Glioma	United States	Azurity Pharmaceuticals, Inc.	23 Sep 1996
Astrocytoma	China	Tianjin Jinyao Pharmaceutical Co., Ltd.	01 Jan 1981
Brain Cancer	United States	Avet Lifesciences Ltd.	07 Mar 1977

Developing

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Malignant glioma of brain	Phase 3	China	Shandong Lanjin Biological Engineering Co., Ltd.	21 Oct 2013
Oligodendroglioma	Phase 3	China	-	01 Aug 2012
WHO Grade III Mixed Glioma	Phase 3	China	-	01 Aug 2012
Gliosarcoma	Phase 2	United States	Eisai, Inc.	01 Dec 2008
Recurrent Glioblastoma	Phase 2	United States	Direct Therapeutics, Inc.	01 Jun 2000
Recurrent Malignant Glioma	Phase 2	United States	Direct Therapeutics, Inc.	01 Jun 2000
Glioblastoma Multiforme	Phase 2	United States	Direct Therapeutics, Inc.	01 Sep 1995

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT04728633 (Phase II prospective trial, ASCO2025)	Phase 2	Liver metastases First line	28	High-dose BCNU chemoembolization	lnemhdwzkl(msyiegeinu) = nxgewquzdq upbregshxz (rhekqcynhb ) View more	Positive	30 May 2025
NCT00801216 (SCNSL1, CTgov)	Phase 2	B-Cell Lymphoma	40	etoposide+cyclophosphamide+carmustine+Rituximab+methotrexate+Thiotepa+cytarabine	pxgjoxiihd = ktnvqdigdk hcjgxjgpfk (dairjasbej, fnvynytqnu - huqwclpqxt) View more	-	10 Dec 2024
NCT01511562 (Alliance 51101, Pubmed)	Phase 2	Primary Central Nervous System Lymphoma Consolidation	113	Myeloablative consolidation supported by autologous stem cell transplantation	elpwifbgxw(nevptxdqyl) = hrfmgikhws jackvjxzsy (emapocvsgv )	Positive	10 Apr 2024
				Non-myeloablative consolidation with infusional etoposide plus cytarabine (EA)	elpwifbgxw(nevptxdqyl) = mpvxqwkzfo jackvjxzsy (emapocvsgv )
Tandem Meetings ASTCT and CIBMTR2022	Not Applicable	Primary Central Nervous System Lymphoma	-	BCNU and Thiotepa with 1 Day-of-Rest	tqstqfmxuc(orddkpfmxz) = djnahahdod iueqsrmqki (npbhvhzlxk ) View more	-	01 Mar 2022
ESMO2021	Not Applicable	Glioblastoma	110	Carmustine wafers (Gliadel)	ceoptkovlb(ilohniwpbj) = vlxskrehhq byvgeubzkx (xpnslmchno ) View more	-	16 Sep 2021
				carmustine implants (No wafers)	ceoptkovlb(ilohniwpbj) = rzoqbgsykg byvgeubzkx (xpnslmchno ) View more
Tandem Meetings ASTCT and CIBMTR2021	Not Applicable	Refractory Lymphoma	-	Bendamustine-EAM conditioning	yaqemltzws(sumzvtvkel) = ICU admission was more common in the Bendamustine-EAM conditioning group boatgkgbve (tklmczcmsa ) View more	Positive	01 Mar 2021
				Carmustine conditioning
NCT02059239 (CTgov)	Phase 1/2	Hodgkin's Lymphoma \| Recurrent Lymphoma \| Non-Hodgkin's lymphoma refractory ... View more	34	Autologous Stem Cell Transplantation+Etoposide+bendamustine+Carmustine+Melphalan+Rituximab+Cytarabine+Alemtuzumab (Chemo Plus Autologous Transplantation)	znxigvxtyg = fnwbesovzh xfpeuhowjy (wrrbbdybsj, ftevifgfxz - touxnyemgl) View more	-	21 Feb 2021
				Allogeneic Stem Cell Transplantation+Etoposide+bendamustine+Carmustine+Melphalan+Rituximab+Cytarabine+Alemtuzumab (Chemo Plus Allogeneic Transplantation)	znxigvxtyg = yttxcrcnsf xfpeuhowjy (wrrbbdybsj, eeeszjewze - arrtgbyfng) View more
NCT00004031 (SWOG-9704, CTgov)	Phase 3	Aggressive Non-Hodgkin Lymphoma \| CD20 positive B-Cell Lymphoma	397	stem cell support+Cyclophosphamide+prednisone+doxorubicin hydrochloride+Vincristine Sulfate+rituximab (CHOP/CHOP-R x 3)	jzhpimjqrw = efensrbyek dvpfselvvc (buukxssfpq, jdtvkdbdpz - nyylumbtkf) View more	-	02 Feb 2021
				radiation therapy+etoposide+Cyclophosphamide+prednisone+carmustine+doxorubicin hydrochloride+Vincristine Sulfate+rituximab (CHOP/CHOP-R x 1 + Autologous Stem Cell Transplant)	jzhpimjqrw = nnycdvqvgu dvpfselvvc (buukxssfpq, ujlptzutrb - jvxsscrxad) View more
NCT00591630 (CTgov)	Phase 2	Diffuse Large B-Cell Lymphoma \| Diffuse large B-cell lymphoma recurrent	30	BEAM+Rituximab (Group 1 - Zevalin + BEAM + Rituximab +Stem Cell Transplant)	ipfewiwjmx = imxqcoheub wqslnfsbnm (zzlyftenxi, jjsmqfuqyw - vcbzeufniy) View more	-	02 Feb 2021
				BEAM (Group 1 - Zevalin + BEAM + Stem Cell Transplant)	ipfewiwjmx = inirglrjni wqslnfsbnm (zzlyftenxi, zjruakqxhx - skuugrovlq) View more
EBMT2020	Not Applicable	Lymphoma	8	Thiotepa, Carmustine and Etoposide Conditioning	pehxogtnrq(uxfroiljtz) = hbzovpyftm zdqhurahrb (oibzniegmi ) View more	Positive	29 Aug 2020